Table 3.
Published studies of therapy in CAD.
| Target | Treatment | Study (Reference) | Study design | ORR1 (%) | CR2 rate (%) | Median response duration (months) | Toxicity |
|---|---|---|---|---|---|---|---|
| B-cell directed theapies | Rituximab monotherapy | Berentsen et al., 2004 (78) Schöllkopf et al., 2006 (79) |
Prospective, non-randomized | 45-55 | <5 | 6.5-11 | Low |
| Rituximab plus fludarabine | Berentsen et al., 2010 (80) | Prospective, non-randomized | 76 | 21 | >66 | Significant | |
| Rituximab plus bendamustine | Berentsen et al., 2017 (81) Berentsen at al. 2020 (61) |
Prospective, non-randomized | 78 | 53 | >88 | Moderate, manageable | |
| Bortezomib monotherapy | Rossi et al., 2018 (82) | Prospective, non-randomized | 32 | 16 | >16 | Low | |
| Ibrutinib monotherapy | Jalink et al., 2021 (83) | Retrospective | 100 | NR1 | ND1 | Low | |
| Complement-directed therapies | Sutimlimab | Röth et al. (CARDINAL study) 2021 (70) | Prospective, non-randomized | >733 | NR1 | >24 | Low |
| Röth et al. (CADENZA study) 2021 (77) | Prospective, randomized | ||||||
| Pegcetacoplan | Grossi et al., 2018 | Part of prospective phase 2 study | ND/high3 | NR1 | ND1 | Low |
1ORR, overall response rate; ND, not determined; NR, not relevant.
2CR, complete response. Criteria for CR included eradication of detectable bone marrow lymphoproliferative disorder.
3ORR was not an endpoint of this study. Estimated ORR is based on data from the original publication.